1
|
Lazo JS, Isbell KN, Vasa SA, Llaneza DC, Rastelli EJ, Wipf P, Sharlow ER. Disruption of Ovarian Cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase. J Pharmacol Exp Ther 2023; 384:429-438. [PMID: 36627205 PMCID: PMC9976793 DOI: 10.1124/jpet.122.001401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 11/28/2022] [Accepted: 12/19/2022] [Indexed: 01/11/2023] Open
Abstract
Protein tyrosine phosphatase type IVA member 3 (PTP4A3 or PRL-3) is a nonreceptor, oncogenic, dual-specificity phosphatase that is highly expressed in many human tumors, including ovarian cancer, and is associated with a poor patient prognosis. Recent studies suggest that PTP4A3 directly dephosphorylates SHP-2 phosphatase as part of a STAT3-PTP4A3 feedforward loop and directly dephosphorylates p38 kinase. The goal of the current study was to examine the effect of a PTP4A phosphatase inhibitor, 7-imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione (JMS-053), on ovarian cancer STAT3, SHP-2, and p38 kinase phosphorylation. JMS-053 caused a concentration- and time-dependent decrease in the activated form of STAT3, Y705 phospho-STAT3, in ovarian cancer cells treated in vitro. In contrast, the phosphorylation status of two previously described direct PTP4A3 substrates, SHP-2 phosphatase and p38 kinase, were rapidly increased with JMS-053 treatment. We generated A2780 and OVCAR4 ovarian cancer cells resistant to JMS-053, and the resulting cells were not crossresistant to paclitaxel, cisplatin, or teniposide. JMS-053-resistant A2780 and OVCAR4 cells exhibited a 95% and 50% decrease in basal Y705 phospho-STAT3, respectively. JMS-053-resistant OVCAR4 cells had an attenuated phosphorylation and migratory response to acute exposure to JMS-053. These results support a regulatory role for PTP4A phosphatase in ovarian cancer cell STAT3 and p38 signaling circuits. SIGNIFICANCE STATEMENT: This study demonstrates that chemical inhibition of PTP4A phosphatase activity with JMS-053 decreases STAT3 activation and increases SHP-2 phosphatase and p38 kinase phosphorylation activation in ovarian cancer cells. The newly developed JMS-053-resistant ovarian cancer cells should provide useful tools to further probe the role of PTP4A phosphatase in ovarian cancer cell survival and cell signaling.
Collapse
Affiliation(s)
- John S Lazo
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| | - Kelly N Isbell
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| | - Sai Ashish Vasa
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| | - Danielle C Llaneza
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| | - Ettore J Rastelli
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| | - Peter Wipf
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| | - Elizabeth R Sharlow
- Department of Pharmacology, University of Virginia, Charlottesville, Virginia (J.S.L., D.C.L., E.R.S.); KeViRx, Inc., Charlottesville, Virginia (J.S.L., K.N.I., S.A.V., E.R.S.); and Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., P.W.)
| |
Collapse
|
2
|
Adel M. Kamal El-Dean, Geies AA, Hassanien R, Abdel-Wadood FK, El-Naeem EEA. Novel Synthesis, Reactions, and Biological Study of New Morpholino-Thieno[2,3-c][2,7]Naphthyridines as Anti-Cancer and Anti-Microbial Agents. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2022. [DOI: 10.1134/s1068162022040021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
3
|
Buglioni L, Raymenants F, Slattery A, Zondag SDA, Noël T. Technological Innovations in Photochemistry for Organic Synthesis: Flow Chemistry, High-Throughput Experimentation, Scale-up, and Photoelectrochemistry. Chem Rev 2022; 122:2752-2906. [PMID: 34375082 PMCID: PMC8796205 DOI: 10.1021/acs.chemrev.1c00332] [Citation(s) in RCA: 208] [Impact Index Per Article: 104.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Indexed: 02/08/2023]
Abstract
Photoinduced chemical transformations have received in recent years a tremendous amount of attention, providing a plethora of opportunities to synthetic organic chemists. However, performing a photochemical transformation can be quite a challenge because of various issues related to the delivery of photons. These challenges have barred the widespread adoption of photochemical steps in the chemical industry. However, in the past decade, several technological innovations have led to more reproducible, selective, and scalable photoinduced reactions. Herein, we provide a comprehensive overview of these exciting technological advances, including flow chemistry, high-throughput experimentation, reactor design and scale-up, and the combination of photo- and electro-chemistry.
Collapse
Affiliation(s)
- Laura Buglioni
- Micro
Flow Chemistry and Synthetic Methodology, Department of Chemical Engineering
and Chemistry, Eindhoven University of Technology, Het Kranenveld, Bldg 14—Helix, 5600 MB, Eindhoven, The Netherlands
- Flow
Chemistry Group, van ’t Hoff Institute for Molecular Sciences
(HIMS), Universiteit van Amsterdam (UvA), Science Park 904, 1098 XH, Amsterdam, The Netherlands
| | - Fabian Raymenants
- Flow
Chemistry Group, van ’t Hoff Institute for Molecular Sciences
(HIMS), Universiteit van Amsterdam (UvA), Science Park 904, 1098 XH, Amsterdam, The Netherlands
| | - Aidan Slattery
- Flow
Chemistry Group, van ’t Hoff Institute for Molecular Sciences
(HIMS), Universiteit van Amsterdam (UvA), Science Park 904, 1098 XH, Amsterdam, The Netherlands
| | - Stefan D. A. Zondag
- Flow
Chemistry Group, van ’t Hoff Institute for Molecular Sciences
(HIMS), Universiteit van Amsterdam (UvA), Science Park 904, 1098 XH, Amsterdam, The Netherlands
| | - Timothy Noël
- Flow
Chemistry Group, van ’t Hoff Institute for Molecular Sciences
(HIMS), Universiteit van Amsterdam (UvA), Science Park 904, 1098 XH, Amsterdam, The Netherlands
| |
Collapse
|
4
|
Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer. Biomolecules 2021; 11:biom11070969. [PMID: 34209460 PMCID: PMC8329922 DOI: 10.3390/biom11070969] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 06/26/2021] [Accepted: 06/28/2021] [Indexed: 01/02/2023] Open
Abstract
High grade serous ovarian cancer (OvCa) frequently becomes drug resistant and often recurs. Consequently, new drug targets and therapies are needed. Bioinformatics-based studies uncovered a relationship between high Protein Tyrosine Phosphatase of Regenerating Liver-3 (PRL3 also known as PTP4A3) expression and poor patient survival in both early and late stage OvCa. PTP4A3 mRNA levels were 5-20 fold higher in drug resistant or high grade serous OvCa cell lines compared to nonmalignant cells. JMS-053 is a potent allosteric small molecule PTP4A3 inhibitor and to explore further the role of PTP4A3 in OvCa, we synthesized and interrogated a series of JMS-053-based analogs in OvCa cell line-based phenotypic assays. While the JMS-053 analogs inhibit in vitro PTP4A3 enzyme activity, none were superior to JMS-053 in reducing high grade serous OvCa cell survival. Because PTP4A3 controls cell migration, we interrogated the effect of JMS-053 on this cancer-relevant process. Both JMS-053 and CRISPR/Cas9 PTP4A3 depletion blocked cell migration. The inhibition caused by JMS-053 required the presence of PTP4A3. JMS-053 caused additive or synergistic in vitro cytotoxicity when combined with paclitaxel and reduced in vivo OvCa dissemination. These results indicate the importance of PTP4A3 in OvCa and support further investigations of the lead inhibitor, JMS-053.
Collapse
|
5
|
Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway. Bioorg Med Chem Lett 2021; 46:128167. [PMID: 34089839 DOI: 10.1016/j.bmcl.2021.128167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 05/25/2021] [Accepted: 05/27/2021] [Indexed: 02/07/2023]
Abstract
We developed JMS-053, a potent inhibitor of the dual specificity phosphatase PTP4A3 that is potentially suitable for cancer therapy. Due to the emerging role of the unfolded protein response (UPR) in cancer pathology, we sought to identify derivatives that combine PTP4A3 inhibition with induction of endoplasmatic reticulum (ER) stress, with the goal to generate more potent anticancer agents. We have now generated bifunctional analogs that link the JMS-053 pharmacophore to an adamantyl moiety and act in concert with the phosphatase inhibitor to induce ER stress and cell death. The most potent compound in this series, 7a, demonstrated a ca. 5-fold increase in cytotoxicity in a breast cancer cell line and strong activation of UPR and ER stress response genes in spite of a ca. 13-fold decrease in PTP4A3 inhibition. These results demonstrate that the combination of phosphatase inhibition with UPR/ER-stress upregulation potentiates efficacy.
Collapse
|
6
|
Zhu Y, Hui L, Zhang S. A Palladium(0)‐Catalyzed C4 Site‐Selective C−H Difluoroalkylation of Isoquinolin‐1(
2H
)‐Ones. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202001614] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- You‐Quan Zhu
- State Key Laboratory of Elemento-Organic Chemistry College of Chemistry Nankai University Tianjin 300071
| | - Li‐Wen Hui
- State Key Laboratory of Elemento-Organic Chemistry College of Chemistry Nankai University Tianjin 300071
| | - Shi‐Bo Zhang
- State Key Laboratory of Elemento-Organic Chemistry College of Chemistry Nankai University Tianjin 300071
| |
Collapse
|
7
|
Rastelli EJ, Yue D, Millard C, Wipf P. 3D-printed cartridge system for in-flow photo-oxygenation of 7-aminothienopyridinones. Tetrahedron 2021. [DOI: 10.1016/j.tet.2020.131875] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
8
|
Czub MP, Boulton AM, Rastelli EJ, Tasker NR, Maskrey TS, Blanco IK, McQueeney KE, Bushweller JH, Minor W, Wipf P, Sharlow ER, Lazo JS. Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin. Mol Pharmacol 2020; 98:648-657. [PMID: 32978326 DOI: 10.1124/molpharm.120.000131] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 09/08/2020] [Indexed: 12/19/2022] Open
Abstract
Protein tyrosine phosphatase (PTP) 4A3 is frequently overexpressed in human solid tumors and hematologic malignancies and is associated with tumor cell invasion, metastasis, and a poor patient prognosis. Several potent, selective, and allosteric small molecule inhibitors of PTP4A3 were recently identified. A lead compound in the series, JMS-053 (7-imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione), has a long plasma half-life (∼ 24 hours) in mice, suggesting possible binding to serum components. We confirmed by isothermal titration calorimetry that JMS-053 binds to human serum albumin. A single JMS-053 binding site was identified by X-ray crystallography in human serum albumin at drug site 3, which is also known as subdomain IB. The binding of JMS-053 to human serum albumin, however, did not markedly alter the overall albumin structure. In the presence of serum albumin, the potency of JMS-053 as an in vitro inhibitor of PTP4A3 and human A2780 ovarian cancer cell growth was reduced. The reversible binding of JMS-053 to serum albumin may serve to increase JMS-053's plasma half-life and thus extend the delivery of the compound to tumors. SIGNIFICANCE STATEMENT: X-ray crystallography revealed that a potent, reversible, first-in-class small molecule inhibitor of the oncogenic phosphatase protein tyrosine phosphatase 4A3 binds to at least one site on human serum albumin, which is likely to extend the compound's plasma half-life and thus assist in drug delivery into tumors.
Collapse
Affiliation(s)
- Mateusz P Czub
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Adam M Boulton
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Ettore J Rastelli
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Nikhil R Tasker
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Taber S Maskrey
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Isabella K Blanco
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Kelley E McQueeney
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - John H Bushweller
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Wladek Minor
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Peter Wipf
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - Elizabeth R Sharlow
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| | - John S Lazo
- Departments of Molecular Physiology and Biological Physics (M.P.C., A.M.B., J.H.B., W.M.) and Pharmacology (K.E.M., E.R.S., J.S.L.) and Center for Structural Genomics of Infectious Diseases (CSGID) (M.P.C., W.M.), University of Virginia, Charlottesville, Virginia; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania (E.J.R., N.R.T., T.S.M., P.W.); and KeViRx, Inc., Charlottesville, Virginia (I.K.B., E.R.S., J.S.L.)
| |
Collapse
|
9
|
Lazo JS, Blanco IK, Tasker NR, Rastelli EJ, Burnett JC, Garrott SR, Hart DJ, McCloud RL, Hsu KL, Wipf P, Sharlow ER. Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase. J Pharmacol Exp Ther 2019; 371:652-662. [PMID: 31601683 PMCID: PMC6856870 DOI: 10.1124/jpet.119.262188] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 10/03/2019] [Indexed: 12/11/2022] Open
Abstract
Oncogenic protein tyrosine phosphatases (PTPs) are overexpressed in numerous human cancers but they have been challenging pharmacological targets. The emblematic oncogenic PTP4A tyrosine phosphatase family regulates many fundamental malignant processes. 7-Imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione (JMS-053) is a novel, potent, and selective PTP4A inhibitor but its mechanism of action has not been fully elucidated, nor has the chemotype been fully investigated. Because tyrosine phosphatases are notoriously susceptible to oxidation, we interrogated JMS-053 and three newly synthesized analogs with specific attention on the role of oxidation. JMS-053 and its three analogs were potent in vitro PTP4A3 inhibitors, but 7-imino-5-methyl-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione (NRT-870-59) appeared unique among the thienopyridinediones with respect to its inhibitory specificity for PTP4A3 versus both a PTP4A3 A111S mutant and an oncogenic dual specificity tyrosine phosphatase, CDC25B. Like JMS-053, NRT-870-59 was a reversible PTP4A3 inhibitor. All of the thienopyridinediones retained cytotoxicity against human ovarian and breast cancer cells grown as pathologically relevant three-dimensional spheroids. Inhibition of cancer cell colony formation by NRT-870-59, like JMS-053, required PTP4A3 expression. JMS-053 failed to generate significant detectable reactive oxygen species in vitro or in cancer cells. Mass spectrometry results indicated no disulfide bond formation or oxidation of the catalytic Cys104 after in vitro incubation of PTP4A3 with JMS-053 or NRT-870-59. Gene expression profiling of cancer cells exposed to JMS-053 phenocopied many of the changes seen with the loss of PTP4A3 and did not indicate oxidative stress. These data demonstrate that PTP4A phosphatases can be selectively targeted with small molecules that lack prominent reactive oxygen species generation and encourage further studies of this chemotype. SIGNIFICANCE STATEMENT: Protein tyrosine phosphatases are emerging as important contributors to human cancers. We report on a new class of reversible protein phosphatase small molecule inhibitors that are cytotoxic to human ovarian and breast cancer cells, do not generate significant reactive oxygen species in vitro and in cells, and could be valuable lead molecules for future studies of PTP4A phosphatases.
Collapse
Affiliation(s)
- John S Lazo
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Isabella K Blanco
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Nikhil R Tasker
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Ettore J Rastelli
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - James C Burnett
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Sharon R Garrott
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Duncan J Hart
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Rebecca L McCloud
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Ku-Lung Hsu
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Peter Wipf
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Elizabeth R Sharlow
- Departments of Pharmacology (J.S.L., I.K.B., S.R.G., D.J.H., E.R.S.) and Chemistry (J.S.L., R.L.M., K.-L.H.), University of Virginia, Charlottesville, Virginia; and Department of Chemistry (N.R.T., E.J.R., J.C.B., P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania
| |
Collapse
|
10
|
Atoui D, Li H, Ben Salem R, Roisnel T, Soulé J, Doucet H. A Straightforward One‐Step Access to Ticlopidine Derivatives Arylated at the C5‐Position of the Thienyl Ring via Pd‐Catalyzed Direct Arylations. ASIAN J ORG CHEM 2019. [DOI: 10.1002/ajoc.201900609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Dhieb Atoui
- CNRS, ISCR-UMR 6226Univ Rennes F-35000 Rennes France
- Laboratoire de Chimie Organique LR 17ES08 Faculté des Sciences de SfaxUniversité de Sfax BP 1171, Route de la Soukra km 4 3038 Sfax Tunisia
| | - Haoran Li
- CNRS, ISCR-UMR 6226Univ Rennes F-35000 Rennes France
| | - Ridha Ben Salem
- Laboratoire de Chimie Organique LR 17ES08 Faculté des Sciences de SfaxUniversité de Sfax BP 1171, Route de la Soukra km 4 3038 Sfax Tunisia
| | | | | | - Henri Doucet
- CNRS, ISCR-UMR 6226Univ Rennes F-35000 Rennes France
| |
Collapse
|
11
|
Tasker NR, Rastelli EJ, Burnett JC, Sharlow ER, Lazo JS, Wipf P. Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors. Bioorg Med Chem Lett 2019; 29:2008-2015. [PMID: 31307888 DOI: 10.1016/j.bmcl.2019.06.048] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 06/24/2019] [Accepted: 06/25/2019] [Indexed: 12/17/2022]
Abstract
Protein tyrosine phosphatases (PTPs) are emerging new targets for drug discovery. PTPs and protein tyrosine kinases (PTKs) maintain cellular homeostasis through opposing roles: tyrosine O-dephosphorylation and -phosphorylation, respectively. An imbalance in the phosphorylation equilibrium results in aberrant protein signaling and pathophysiological conditions. PTPs have historically been considered 'undruggable', in part due to a lack of evidence defining their relationship to disease causality and a focus on purely competitive inhibitors. However, a better understanding of protein-protein interfaces and shallow active sites has recently renewed interest in the pursuit of allosteric and orthosteric modulators of targets outside the major druggable protein families. While their biological mechanism of action still remains to be clarified, PTP4A1-3 (also referred to as PRL1-3) are validated oncology targets and play an important role in cell proliferation, metastasis, and tumor angiogenesis. In this Digest, recent syntheses and structure-activity relationships (SAR) of small molecule inhibitors (SMIs) of PTP4A1-3 are summarized, and enzyme docking studies of the most potent chemotype are highlighted. In particular, the thienopyridone scaffold has emerged as a potent lead structure to interrogate the function and druggability of this dual-specificity PTP.
Collapse
Affiliation(s)
- Nikhil R Tasker
- University of Pittsburgh, Department of Chemistry, 219 Parkman Avenue, Pittsburgh, PA 15260, USA
| | - Ettore J Rastelli
- University of Pittsburgh, Department of Chemistry, 219 Parkman Avenue, Pittsburgh, PA 15260, USA
| | - James C Burnett
- University of Pittsburgh, Department of Chemistry, 219 Parkman Avenue, Pittsburgh, PA 15260, USA
| | - Elizabeth R Sharlow
- University of Virginia, Department of Pharmacology, 1340 Jefferson Park Avenue, Charlottesville, VA 22908, USA
| | - John S Lazo
- University of Virginia, Department of Pharmacology, 1340 Jefferson Park Avenue, Charlottesville, VA 22908, USA
| | - Peter Wipf
- University of Pittsburgh, Department of Chemistry, 219 Parkman Avenue, Pittsburgh, PA 15260, USA.
| |
Collapse
|